JP2019506394A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019506394A5 JP2019506394A5 JP2018538085A JP2018538085A JP2019506394A5 JP 2019506394 A5 JP2019506394 A5 JP 2019506394A5 JP 2018538085 A JP2018538085 A JP 2018538085A JP 2018538085 A JP2018538085 A JP 2018538085A JP 2019506394 A5 JP2019506394 A5 JP 2019506394A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- acid sequence
- amino acid
- cdr3
- cdr2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 81
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 24
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 23
- 210000004899 c-terminal region Anatomy 0.000 claims 17
- 210000002865 immune cell Anatomy 0.000 claims 17
- 230000004068 intracellular signaling Effects 0.000 claims 7
- 108091033319 polynucleotide Proteins 0.000 claims 5
- 102000040430 polynucleotide Human genes 0.000 claims 5
- 239000002157 polynucleotide Substances 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 239000013604 expression vector Substances 0.000 claims 3
- 230000011664 signaling Effects 0.000 claims 3
- 206010073128 Anaplastic oligodendroglioma Diseases 0.000 claims 2
- 206010003571 Astrocytoma Diseases 0.000 claims 2
- 206010014967 Ependymoma Diseases 0.000 claims 2
- 208000000172 Medulloblastoma Diseases 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 208000007641 Pinealoma Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 206010061424 Anal cancer Diseases 0.000 claims 1
- 208000007860 Anus Neoplasms Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 102000001301 EGF receptor Human genes 0.000 claims 1
- 108060006698 EGF receptor Proteins 0.000 claims 1
- 206010014968 Ependymoma malignant Diseases 0.000 claims 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 208000009277 Neuroectodermal Tumors Diseases 0.000 claims 1
- 201000010133 Oligodendroglioma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010050487 Pinealoblastoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000008938 Rhabdoid tumor Diseases 0.000 claims 1
- 206010073334 Rhabdoid tumour Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 206010043276 Teratoma Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 206010002224 anaplastic astrocytoma Diseases 0.000 claims 1
- 208000014534 anaplastic ependymoma Diseases 0.000 claims 1
- 201000011165 anus cancer Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000010932 epithelial neoplasm Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 239000003292 glue Substances 0.000 claims 1
- 208000026436 grade III glioma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 108020001756 ligand binding domains Proteins 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 206010027191 meningioma Diseases 0.000 claims 1
- 201000004058 mixed glioma Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000003113 pineoblastoma Diseases 0.000 claims 1
- 206010035059 pineocytoma Diseases 0.000 claims 1
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 claims 1
- 238000003259 recombinant expression Methods 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662281533P | 2016-01-21 | 2016-01-21 | |
| US62/281,533 | 2016-01-21 | ||
| US201662431758P | 2016-12-08 | 2016-12-08 | |
| US62/431,758 | 2016-12-08 | ||
| PCT/IB2017/050108 WO2017125830A1 (en) | 2016-01-21 | 2017-01-10 | Chimeric antigen receptors targeting epidermal growth factor receptor variant iii |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020177399A Division JP7198797B2 (ja) | 2016-01-21 | 2020-10-22 | 上皮成長因子受容体変異体ｉｉｉを標的とするキメラ抗原受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019506394A JP2019506394A (ja) | 2019-03-07 |
| JP2019506394A5 true JP2019506394A5 (https=) | 2020-02-20 |
| JP6823659B2 JP6823659B2 (ja) | 2021-02-03 |
Family
ID=57868301
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018538085A Active JP6823659B2 (ja) | 2016-01-21 | 2017-01-10 | 上皮成長因子受容体変異体ｉｉｉを標的とするキメラ抗原受容体 |
| JP2020177399A Active JP7198797B2 (ja) | 2016-01-21 | 2020-10-22 | 上皮成長因子受容体変異体ｉｉｉを標的とするキメラ抗原受容体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020177399A Active JP7198797B2 (ja) | 2016-01-21 | 2020-10-22 | 上皮成長因子受容体変異体ｉｉｉを標的とするキメラ抗原受容体 |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US10259876B2 (https=) |
| EP (1) | EP3405481B1 (https=) |
| JP (2) | JP6823659B2 (https=) |
| KR (1) | KR102479606B1 (https=) |
| CN (1) | CN108699124A (https=) |
| AU (1) | AU2017208834B2 (https=) |
| BR (1) | BR112018014585A2 (https=) |
| CA (1) | CA2954014A1 (https=) |
| DK (1) | DK3405481T5 (https=) |
| EA (1) | EA201891641A1 (https=) |
| ES (1) | ES2942362T3 (https=) |
| IL (1) | IL260666B2 (https=) |
| MX (1) | MX2018008978A (https=) |
| MY (1) | MY192474A (https=) |
| NZ (1) | NZ744821A (https=) |
| PH (1) | PH12018501473B1 (https=) |
| RU (1) | RU2751662C2 (https=) |
| SA (1) | SA518392058B1 (https=) |
| SG (2) | SG10202111458RA (https=) |
| TW (2) | TWI755547B (https=) |
| UA (1) | UA125252C2 (https=) |
| WO (1) | WO2017125830A1 (https=) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180083868A (ko) | 2015-10-30 | 2018-07-23 | 알레타 바이오쎄라퓨틱스, 인크. | 종양 형질도입용 조성물 및 방법 |
| JP7115982B2 (ja) | 2015-10-30 | 2022-08-09 | アレタ・バイオセラピューティクス・インコーポレイテッド | 癌の治療のための組成物及び方法 |
| US10221242B2 (en) | 2016-01-21 | 2019-03-05 | Pfizer Inc. | Antibodies specific for epidermal growth factor receptor variant III and their uses |
| EA201891641A1 (ru) * | 2016-01-21 | 2019-01-31 | Пфайзер Инк. | Химерные антигенные рецепторы, нацеленные на вариант iii рецептора эпидермального фактора роста |
| MA46995A (fr) | 2016-12-03 | 2019-10-09 | Acerta Pharma Bv | Méthodes et compositions pour l'utilisation de lymphocytes t thérapeutiques en association avec des inhibiteurs de kinase |
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| AU2018275894B2 (en) | 2017-06-02 | 2025-04-24 | Juno Therapeutics, Inc. | Articles of manufacture and methods for treatment using adoptive cell therapy |
| CA3096202A1 (en) * | 2018-04-06 | 2019-10-10 | The Regents Of The University Of California | Methods of treating egfrviii expressing glioblastomas |
| CA3095757A1 (en) | 2018-04-06 | 2019-10-10 | The Regents Of The University Of California | Methods of treating glioblastomas |
| JP2021532742A (ja) * | 2018-07-26 | 2021-12-02 | ナンジン レジェンド バイオテック カンパニー, リミテッドNanjing Legend Biotech Co., Ltd. | Ｎｅｆを含むｔ細胞及びその生成方法 |
| CN109265561B (zh) * | 2018-09-25 | 2021-05-25 | 山东兴瑞生物科技有限公司 | 抗EGFRvⅢ安全型嵌合抗原受体、其制备方法、利用其修饰的NK细胞及应用 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| EP3883955A1 (en) * | 2018-11-19 | 2021-09-29 | Board of Regents, The University of Texas System | A modular, polycistronic vector for car and tcr transduction |
| SG11202105353PA (en) * | 2018-12-01 | 2021-06-29 | Allogene Therapeutics Inc | Chimeric antigen receptors targeting b-cell maturation antigen and methods of use thereof |
| SG10202105788SA (en) * | 2018-12-21 | 2021-06-29 | Hoffmann La Roche | Antibodies binding to cd3 |
| ES2974424T3 (es) * | 2019-01-17 | 2024-06-27 | Immunocore Ltd | Formulaciones |
| CN111454358A (zh) * | 2019-01-18 | 2020-07-28 | 四川科伦博泰生物医药股份有限公司 | 一种嵌合抗原受体及其应用 |
| WO2020190771A1 (en) * | 2019-03-15 | 2020-09-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric adaptor and kinase signaling proteins and their use in immunotherapy |
| WO2021003297A1 (en) * | 2019-07-02 | 2021-01-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies that bind egfrviii and their use |
| WO2021022044A1 (en) * | 2019-07-31 | 2021-02-04 | Forty Seven, Inc. | Depletion regimes for engineered t-cell or nk-cell therapy |
| US20220401537A1 (en) * | 2019-09-16 | 2022-12-22 | Fred Hutchinson Cancer Research Center | Chimeric receptor proteins and uses thereof |
| KR20220070215A (ko) * | 2019-10-01 | 2022-05-30 | 엡실로겐 리미티드 | 하이브리드 항체 |
| AU2020415318A1 (en) * | 2019-12-23 | 2022-07-14 | Cellectis | New mesothelin specific chimeric antigen receptors (CAR) for solid tumors cancer immunotherapy |
| CN115103857B (zh) * | 2019-12-28 | 2025-12-19 | 上海细胞治疗集团股份有限公司 | 表达免疫调节分子的细胞和表达免疫调节分子的系统 |
| CN111019959B (zh) * | 2019-12-30 | 2022-09-13 | 北京立康生命科技有限公司 | 一种体外转录mRNA的核苷酸分子、呈递细胞及应用 |
| WO2021150936A1 (en) * | 2020-01-22 | 2021-07-29 | City Of Hope | Oncolytic virus compositions including il-15 complex and methods for the treatment of cancer |
| WO2022140388A1 (en) | 2020-12-21 | 2022-06-30 | Allogene Therapeutics, Inc. | Protease-activating cd45-gate car |
| CA3204417A1 (en) | 2021-01-29 | 2022-08-04 | Allogene Therapeutics, Inc. | Knockdown or knockout of one or more of tap2, nlrc5, ?2m, trac, rfx5, rfxap and rfxank to mitigate t cell recognition of allogeneic cell products |
| JPWO2023286840A1 (https=) * | 2021-07-16 | 2023-01-19 | ||
| CA3233347A1 (en) * | 2021-09-29 | 2023-04-06 | Anne MARCIL | Humanized anti-egfrviii antibodies and antigen-binding fragments thereof |
| JP2025525779A (ja) | 2022-07-29 | 2025-08-07 | アロジーン セラピューティクス，インコーポレイテッド | 免疫細胞の認識を低減させるために遺伝子発現が低下した、操作された細胞 |
| CN119013303A (zh) * | 2022-08-05 | 2024-11-22 | 北京鼎成肽源生物技术有限公司 | 靶向EGFRvIII的抗体及其在细胞免疫治疗的应用 |
| CN116284435A (zh) * | 2022-09-19 | 2023-06-23 | 卡瑞济(北京)生命科技有限公司 | EGFRvIII嵌合抗原受体及其用途 |
| WO2024201344A1 (en) * | 2023-03-30 | 2024-10-03 | Novocure Gmbh | Compositions, systems, and methods for treating cancer using tumor treating fields and chimeric antigen receptor (car)-immune cells |
| WO2025096560A1 (en) | 2023-10-30 | 2025-05-08 | Allogene Therapeutics, Inc. | Engineered cells |
| CN117659196B (zh) * | 2023-12-12 | 2024-08-23 | 成都优赛诺生物科技有限公司 | 一种靶向cd7的单域抗体、嵌合抗原受体及其应用 |
| CN119912588B (zh) * | 2025-04-01 | 2025-08-12 | 浙江大学 | 嵌合抗原受体、人诱导多能干细胞、髓系前体细胞样巨噬细胞及其制备方法 |
| CN120248142B (zh) * | 2025-06-06 | 2025-09-12 | 上海兴瑞一达生物科技有限公司 | 一种共表达cd47和il-15的双靶点嵌合抗原受体、car-t细胞及其应用 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4754065A (en) | 1984-12-18 | 1988-06-28 | Cetus Corporation | Precursor to nucleic acid probe |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| GB8611832D0 (en) | 1986-05-15 | 1986-06-25 | Holland I B | Polypeptide |
| US5037743A (en) | 1988-08-05 | 1991-08-06 | Zymogenetics, Inc. | BAR1 secretion signal |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| ATE300615T1 (de) | 1990-08-29 | 2005-08-15 | Genpharm Int | Transgene mäuse fähig zur produktion heterologer antikörper |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
| DE69334095T2 (de) | 1992-07-17 | 2007-04-12 | Dana-Farber Cancer Institute, Boston | Verfahren zur intrazellulären Bindung von zielgerichteten Molekülen |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| CA2406864A1 (en) | 2000-02-24 | 2001-08-30 | Life Technologies Corporation | Simultaneous stimulation and concentration of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| CN1427891A (zh) * | 2000-02-25 | 2003-07-02 | 美国政府由(美国)卫生和福利部部长代表 | 具有提高的细胞毒性和产量的抗EGFRvIII的scFv、基于其的免疫毒素、及其应用方法 |
| US20100105136A1 (en) | 2006-10-09 | 2010-04-29 | The General Hospital Corporation | Chimeric t-cell receptors and t-cells targeting egfrviii on tumors |
| EP2633040B1 (en) | 2010-10-27 | 2019-07-10 | Cellectis | Method for increasing the efficiency of double-strand break-induced mutagenesis |
| US9249217B2 (en) | 2010-12-03 | 2016-02-02 | Secretary, DHHS | Bispecific EGFRvIII x CD3 antibody engaging molecules |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| EP2694549B1 (en) | 2011-04-08 | 2018-08-15 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| US20150017136A1 (en) | 2013-07-15 | 2015-01-15 | Cellectis | Methods for engineering allogeneic and highly active t cell for immunotherapy |
| AU2013271428B2 (en) | 2012-06-07 | 2016-08-04 | Duke University | Human bispecific EGFRvIII antibody engaging molecules |
| KR20150029714A (ko) * | 2012-07-13 | 2015-03-18 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 이중특이적 항체의 공-도입에 의한 ｃａｒ 세포의 활성 증강 |
| CN104769103B (zh) | 2012-09-04 | 2018-06-08 | 塞勒克提斯公司 | 多链嵌合抗原受体和其用途 |
| AU2013204922B2 (en) * | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| DK2958943T3 (da) * | 2013-02-20 | 2019-12-09 | Univ Pennsylvania | Behandling af cancer ved anvendelse af humaniseret anti-EGFRvIII kimær antigenreceptor |
| CN105283201B (zh) | 2013-03-14 | 2019-08-02 | 斯克利普斯研究所 | 靶向剂抗体偶联物及其用途 |
| MX2015015638A (es) | 2013-05-13 | 2016-10-28 | Cellectis | Metodos para diseñar celulas t altamente activas para inmunoterapia. |
| PL3546572T3 (pl) | 2013-05-13 | 2024-07-22 | Cellectis | Chimeryczny receptor antygenowy swoisty względem cd19 i jego zastosowania |
| WO2014191128A1 (en) | 2013-05-29 | 2014-12-04 | Cellectis | Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system |
| TR201904121T4 (tr) | 2013-07-09 | 2019-04-22 | The Government Of The United States As Represented By The Secretary Of The Dept Of Health And Human | İnsan bispesifik egfrviii antikoru birleştirme molekülleri. |
| CN105555804B (zh) | 2013-08-07 | 2020-12-25 | 阿菲姆德股份有限公司 | 对EGFRvIII有特异性的抗体结合位点 |
| WO2015092024A2 (en) * | 2013-12-20 | 2015-06-25 | Cellectis | Method of engineering multi-input signal sensitive t cell for immunotherapy |
| MX2017001229A (es) | 2014-07-29 | 2017-05-01 | Pfizer | Receptores de antigenos quimericos especificos de egfrviii para inmunoterapia de cancer. |
| TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Egfrviii及cd3抗體構築體 |
| EA201891641A1 (ru) | 2016-01-21 | 2019-01-31 | Пфайзер Инк. | Химерные антигенные рецепторы, нацеленные на вариант iii рецептора эпидермального фактора роста |
| US10221242B2 (en) | 2016-01-21 | 2019-03-05 | Pfizer Inc. | Antibodies specific for epidermal growth factor receptor variant III and their uses |
-
2017
- 2017-01-10 EA EA201891641A patent/EA201891641A1/ru unknown
- 2017-01-10 SG SG10202111458RA patent/SG10202111458RA/en unknown
- 2017-01-10 UA UAA201808794A patent/UA125252C2/uk unknown
- 2017-01-10 TW TW107120550A patent/TWI755547B/zh active
- 2017-01-10 DK DK17701190.5T patent/DK3405481T5/da active
- 2017-01-10 CN CN201780012883.XA patent/CN108699124A/zh active Pending
- 2017-01-10 NZ NZ744821A patent/NZ744821A/en unknown
- 2017-01-10 RU RU2018130088A patent/RU2751662C2/ru active
- 2017-01-10 MY MYPI2018702481A patent/MY192474A/en unknown
- 2017-01-10 SG SG11201805872SA patent/SG11201805872SA/en unknown
- 2017-01-10 CA CA2954014A patent/CA2954014A1/en active Pending
- 2017-01-10 US US15/402,760 patent/US10259876B2/en active Active
- 2017-01-10 TW TW106100738A patent/TWI634125B/zh active
- 2017-01-10 WO PCT/IB2017/050108 patent/WO2017125830A1/en not_active Ceased
- 2017-01-10 BR BR112018014585A patent/BR112018014585A2/pt not_active Application Discontinuation
- 2017-01-10 MX MX2018008978A patent/MX2018008978A/es unknown
- 2017-01-10 EP EP17701190.5A patent/EP3405481B1/en active Active
- 2017-01-10 KR KR1020187023865A patent/KR102479606B1/ko active Active
- 2017-01-10 ES ES17701190T patent/ES2942362T3/es active Active
- 2017-01-10 AU AU2017208834A patent/AU2017208834B2/en active Active
- 2017-01-10 JP JP2018538085A patent/JP6823659B2/ja active Active
- 2017-01-10 PH PH1/2018/501473A patent/PH12018501473B1/en unknown
-
2018
- 2018-07-19 IL IL260666A patent/IL260666B2/en unknown
- 2018-07-19 SA SA518392058A patent/SA518392058B1/ar unknown
-
2019
- 2019-01-23 US US16/255,348 patent/US11267892B2/en not_active Expired - Fee Related
-
2020
- 2020-10-22 JP JP2020177399A patent/JP7198797B2/ja active Active
-
2022
- 2022-01-27 US US17/586,321 patent/US20220227874A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019506394A5 (https=) | ||
| JP6827583B2 (ja) | Ｄｌｌ３及びｃｄ３に結合する二重特異性抗体構築物 | |
| JP2019506398A5 (https=) | ||
| RU2018130088A (ru) | Химерные антигенные рецепторы, нацеливающиеся на вариант iii рецептора эпидермального фактора роста | |
| JP2017506217A5 (https=) | ||
| JP2017140051A5 (https=) | ||
| NZ750366A (en) | Chimeric antigen receptors targeting bcma and methods of use thereof | |
| WO2011119979A3 (en) | Antibodies to muc16 and methods of use thereof | |
| JP2016508725A5 (https=) | ||
| AR102698A1 (es) | Anticuerpos contra cd73 y sus usos | |
| JP2017520575A5 (https=) | ||
| JP2017527274A5 (https=) | ||
| HRP20150256T1 (hr) | Djelatna sredstva za vezanje notch1-receptora i postupci njihove uporabe | |
| RU2021114500A (ru) | НАПРАВЛЕННОЕ ИНГИБИРОВАНИЕ TGFβ | |
| EA201890294A1 (ru) | Химерный полипептидный комплекс и способы его получения и применения | |
| JP2019193652A (ja) | 前立腺特異幹細胞抗原に対する抗体およびその使用 | |
| WO2006099141A3 (en) | Anti-mesothelin antibodies | |
| RU2018104703A (ru) | Опухолеспецифичное антитело против egfr и его применение | |
| MX2020012081A (es) | Anticuerpos totalmente humanos contra ox40, metodo para preparar los mismos y su uso. | |
| WO2015197016A1 (zh) | 时空可调性抑制病理性靶细胞的系统 | |
| JP2021501567A5 (https=) | ||
| MX2020006871A (es) | Constructo de anticuerpo biespecifico dirigido a muc17 y cd3. | |
| Ahmed et al. | Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody | |
| Sun et al. | A rational designed novel bispecific antibody for the treatment of GBM | |
| FI3806895T3 (fi) | Kasvainkudosta sitovia vasta-aineita ja niiden diagnostisia ja terapeuttisia käyttöjä |